• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer

    10/17/23 8:00:00 AM ET
    $ATAI
    $ATOS
    $ELOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATAI alert in real time by email

    Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/

    Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire)

    Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire)

    Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology company. Prior to Atossa, he was CFO at BioIntelliSense, a commercial stage medtech company focused on remote patient monitoring.

    He was also CFO of atai Life Sciences (NASDAQ:ATAI), completing over $282M in late-stage private financings and led a successful $258M IPO at a $2.3B valuation to support the acquisition of multiple CNS therapeutics assets, and to advance multiple clinical and discovery programs. In addition, Mr. Weaver previously served as CFO of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), where he led their reverse merger and Nasdaq listing. During his career, Mr. Weaver has managed M&A transactions involving oncology products, medical device technologies, and other biotech assets.

    "We are delighted to welcome Greg, who brings decades of expertise leading high-performing teams in the private and public sectors," said Brent Vaughan, Chief Executive Officer at Cognito Therapeutics. "Greg brings a proven track record of success on both the operating and finance sides of our industry, as we advance our pipeline of disease-modifying therapies for neurodegenerative disorders. He is an experienced CFO with a strong track record of fundraising, raising over $2B in his career including in the CNS industry."

    "I am excited to join Cognito at such a dynamic time. The company is advancing its pivotal HOPE study in Alzheimer's disease, and I look forward to working with Brent and the rest of the senior management and scientific teams to help bring innovative non-invasive neuromodulation therapies to patients," said Greg Weaver, CFO, Cognito Therapeutics.

    Mr. Weaver has been involved with development programs that led to multiple FDA approvals and product launches. Several of his companies have had successful exits. Mr. Weaver is a Board Member of Rejuveron Life Sciences and BioIntelliSense, and also serves on the non-profit board of HarborPath. He began his career as a CPA with Arthur Andersen.

    Cognito's pivotal study, HOPE Study for Alzheimer's Disease evaluates a novel wearable device that has the potential to slow the progression of Alzheimer's disease, without the potential safety concerns associated with medications or highly invasive procedures.

    About Cognito Therapeutics

    Cognito Therapeutics is a clinical-stage neurotechnology company developing disease-modifying therapeutic approaches to treat neurodegenerative disorders. Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company's lead therapy is currently in a pivotal study (HOPE) in Alzheimer's Disease and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. For more information, visit www.cognitotx.com. Follow us on Twitter at @cognitotx.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231017630946/en/

    Get the next $ATAI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATAI
    $ATOS
    $ELOX

    CompanyDatePrice TargetRatingAnalyst
    ATAI Life Sciences N.V.
    $ATAI
    10/13/2025$12.00Buy
    Needham
    ATAI Life Sciences N.V.
    $ATAI
    7/29/2025$14.00Outperform
    Oppenheimer
    ATAI Life Sciences N.V.
    $ATAI
    4/4/2025Buy
    Berenberg
    ATAI Life Sciences N.V.
    $ATAI
    11/18/2024$15.00 → $10.00Buy
    H.C. Wainwright
    ATAI Life Sciences N.V.
    $ATAI
    4/3/2024$6.00Hold → Buy
    Maxim Group
    ATAI Life Sciences N.V.
    $ATAI
    11/1/2022$18.00Buy
    Loop Capital
    Eloxx Pharmaceuticals Inc.
    $ELOX
    12/17/2021$4.00Outperform
    Oppenheimer
    ATAI Life Sciences N.V.
    $ATAI
    11/30/2021$25.00Buy
    Maxim Group
    More analyst ratings

    $ATAI
    $ATOS
    $ELOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Daniel Mark James

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    10/21/25 4:10:03 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Daniel Mark James

    3 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    10/21/25 4:05:06 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Barrett Christopher Ryan Cave

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    10/3/25 6:24:41 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $ATOS
    $ELOX
    SEC Filings

    View All

    ATAI Life Sciences N.V. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ATAI Life Sciences N.V. (0001840904) (Filer)

    10/21/25 9:30:16 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by ATAI Life Sciences N.V.

    SCHEDULE 13D/A - ATAI Life Sciences N.V. (0001840904) (Subject)

    10/20/25 4:01:02 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by ATAI Life Sciences N.V.

    424B5 - ATAI Life Sciences N.V. (0001840904) (Filer)

    10/17/25 4:50:22 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $ATOS
    $ELOX
    Financials

    Live finance-specific insights

    View All

    Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

    FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required Strong I-SPY2 Results Reinforce Efficacy of Atossa's Monotherapy at 3-weeks SEATTLE, Aug. 12, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the second quarter ended June 30, 2025 and provided an update on recent company developments. "Atos

    8/12/25 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

    Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events or suicide-related safety signalsMajority of patients deemed ready for discharge at the 90 minutes post-dose assessment, which suggests BPL-003 could fit within t

    7/1/25 6:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

    Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S

    6/2/25 6:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $ATOS
    $ELOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

    SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

    11/12/24 1:32:30 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

    SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

    11/4/24 11:27:58 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by ATAI Life Sciences N.V.

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    9/27/24 7:56:26 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $ATOS
    $ELOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Apeiron Investment Group Ltd. bought $19,000,000 worth of shares (8,675,799 units at $2.19) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    8/18/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Quay Steven C bought $9,887 worth of shares (11,239 units at $0.88), increasing direct ownership by 423% to 13,898 units (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    5/22/25 6:27:25 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Remmel H. Lawrence bought $7,000 worth of shares (10,000 units at $0.70), increasing direct ownership by 3,891% to 10,257 units (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    3/28/25 4:00:03 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $ATOS
    $ELOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

    Investor-focused update underscores enrollment momentum, biomarker strategy, and near-term data readouts designed to de-risk development of (Z)-Endoxifen and other endocrine therapies for DCIS SEATTLE, Oct. 21, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced that Laura J. Esserman, MD, MBA, Professor of Surgery and Radiology at the University of California, San Francisco and Principal Investigator of RECAST™, will speak at the Early Detection Research Conference in Portland, OR, about the Company's collaborative work in the RECAST platform trial fo

    10/21/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

    NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on October 20, 2025, the closing of its public offering of 27,283,750 common shares occurred, inclusive of the closing of the underwriters' option in full to purchase an additional 3,558,750 common shares at the public offering price of $5.48 per share following the exercise by the underwriters of their option on October 17, 2025. The aggregate gross proceeds from the offering, including the gross proceeds from the exercise of the underwriters' option to purchas

    10/20/25 5:29:43 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences Announces Pricing of Public Offering of Common Shares

    NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 23,725,000 common shares, at a price of $5.48 per share. atai has granted the underwriters a 30-day option to purchase up to an additional 3,558,750 common shares at the public offering price, less the underwriting discount. All common shares to be sold in the offering will be sold by atai. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering ex

    10/16/25 10:31:43 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $ATOS
    $ELOX
    Leadership Updates

    Live Leadership Updates

    View All

    Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

    25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial operations with (Z)-endoxifen SEATTLE, Oct. 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces the appointment of Mark Daniel, CPA (WA; inactive), as Chief Financial Officer. Mr. Daniel is a senior finance leader with more than 25 years of experience building the forecasting cadence, systems, and public-company discipline that support revenue scale in global life-science

    10/14/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

    Veteran development leader with successful regulatory approvals record returns to lead late-stage clinical and regulatory programs to address multiple unmet clinical needs SEATTLE, Oct. 1, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS, ", Atossa", or the ", Company", )), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces the appointment of Janet R. Rea, MSPH to its newly created position Senior Vice President, R&D.  Ms. Rea brings more than two decades of strategic research and clinical development expertise, with a success record for regulatory approvals, to oversee late-stage (Z)-endoxifen programs with ne

    10/1/25 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

    SEATTLE, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS, "Atossa" or the "Company")), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, today announces it has appointed CORE IR, a strategic investor relations, public relations, and corporate advisory firm, to support the Company's ongoing investor relations and communications initiatives. CORE IR specializes in emerging and established growth company strategies that enhance investor awareness, strengthen shareholder engagement, and broaden reach to target institutional and retail audiences. Dr. Steven Quay, Chairman and CEO of Atossa, commented, "Ou

    9/17/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $ATOS
    $ELOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on atai Life Sciences N.V. with a new price target

    Needham initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $12.00

    10/13/25 8:51:27 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on atai Life Sciences N.V. with a new price target

    Oppenheimer initiated coverage of atai Life Sciences N.V. with a rating of Outperform and set a new price target of $14.00

    7/29/25 7:39:06 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Berenberg initiated coverage on atai Life Sciences N.V.

    Berenberg initiated coverage of atai Life Sciences N.V. with a rating of Buy

    4/4/25 8:27:07 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care